Aetram Research India - Nifty Pharma - Weekly Sector Outlook
Aetram Research India - Nifty Pharma - Weekly Sector Outlook
Nifty Pharma Extends Bullish Structure; Strength Beyond 27,050 May Target 27,250–27,500, While 26,750 Signals Weakness - 29.08.2026
Current Market Price: 26,991.85
Market Prediction:
- Nifty Pharma is advancing near fresh highs with price firmly above all major moving averages. RSI near 73 shows strong but stretched momentum, while CCI above 145 and ADX near 39 confirm trend strength. Holding 26,750 supports continuation; sustained strength above 27,050 may open 27,250–27,500, although profit-booking risk is elevated.
Upcoming Events:
- US FDA inspection outcomes may influence major pharmaceutical stocks sharply.
- Rupee movements may alter export earnings expectations for pharmaceutical companies.
- Drug pricing policy changes could reshape domestic pharma margin outlook.
Major Support and Resistance
- Support: 26,750 | 26,530 | 26,370
- Resistance: 27,050 | 27,250 | 27,500
Volume Analysis:
- Recent volume supports the advance, though participation has not expanded aggressively near current highs. Rising ADX and positive MACD reinforce momentum, but stronger activity above 27,050 would add conviction for continuation toward next resistance zone.
Final Take Away:
- Nifty Pharma holds technical advantage above 26,750, supported by rising averages and firm momentum. Elevated RSI warrants caution near current highs. Strength above 27,050 favors further upside, while losing 26,750 could encourage consolidation and profit-booking.
Next Week Prediction:
- Next week, Nifty Pharma may keep a positive bias above 26,750; strength beyond 27,050 could extend toward 27,250–27,500, while weakness below 26,750 may trigger profit-booking.
Scenario-Based Outlook
- Bullish Scenario: Above 27,050, price may move toward 27,250–27,500 zone
- Bearish Scenario: Below 26,750, downside risk toward 26,370–26,530 zone
- Neutral Scenario: Between 26,750–27,050, consolidation likely
Disclaimer: This research report is for informational purposes only. This is not an offer to buy or sell securities. Past performance is not indicative of future results. There is no guarantee of returns. Investments in securities are subject to market risks including loss of capital. Investors should consult their financial advisor before making any investment decisions.
